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Zusammenfassung
Hintergrund: Bei der Behandlung fortgeschrittener, inoperabler
Kopf-Hals-Tumoren gilt die kombinierte Chemoradiotherapie für
ausgewählte Patienten als Standard und zeigt bessere Ergeb-
nisse als eine alleinige Strahlentherapie. Die langfristigen Er-
gebnisse dieser Therapie, die Induktion von Zweitmalignomen
(ZWM) und andere Spättoxizitäten sind in der Literatur nicht
genau definiert. Patienten und Methoden: Ausgewertet wurden
100 konsekutive Patienten mit fortgeschrittenen Kopf-Hals-Tu-
moren, die an unserem Zentrum behandelt wurden. Untersucht
wurden die Behandlungsergebnisse, das Auftreten von Spät-
komplikationen und von ZWM. 78 Patienten wurden nach
einem Protokoll behandelt, das Cisplatin, 5-Fluorouracil, Folin-
säure und hyperfraktionierte Bestrahlung kombinierte. 22 Pa-
tienten wurden nach anderen Chemoradiotherapie-Protokollen
behandelt. Das relative Risiko, ein ZWM zu entwickeln, wurde
mit dem Risiko in der Normalbevölkerung verglichen. Ergeb-
nisse: Die kumulative Gesamtüberlebenswahrscheinlichkeit
nach 2 Jahren war 51,1% und nach 4 Jahren 38,7%. Die Wahr-
scheinlichkeit des rezidivfreien Überlebens betrug 39,9% nach 2
Jahren und 36,7% nach 4 Jahren. Insgesamt entwickelten 7 Pa-
tienten ZWM (4 Fälle von Lungenkrebs, 2 Fälle von Darmkrebs,
1 Hautkrebs). Nach 6 Jahren wurde ein kumulatives Risiko von
ZWM von 8,7% beobachtet. Das relative Risiko, an einem ZWM
zu erkranken, war gegenüber der Normalbevölkerung signifi-
kant erhöht (4,45-fach bei Männern). 13 von 38 auswertbaren
Patienten (34,2%) zeigten bei der letzten Kontrolle ernste Spät-
folgen wie narbige Fibrose, Läsionen der Nerven an Hals oder
Schulter, oder brauchten weiterhin eine Trachealkanüle.
Schlussfolgerungen: Die Behandlungsergebnisse und die lang-
fristigen Prognosen unserer unselektionierten Hochrisikopatien-
ten sind unbefriedigend, aber vergleichbar mit den Ergebnis-
sen multizentrischer Studien. Rund 35% der Patienten überle-
ben längerfristig (> 4 Jahre). ZWM treten im allgemeinen früh
auf, haben eine schlechte Prognose und sind mit überwiegen-
der Wahrscheinlichkeit nicht therapiebedingt. Rund 30% der
Langzeitüberlebenden zeigen ernste, oft zu Invalidität führende
Spätfolgen. Die Behandlung und – falls möglich – die Präven-
tion dieser Spätfolgen ist wesentlich für die Lebensqualität der
Patienten, die fortgeschrittene Kopf-Hals-Tumoren überlebt
haben.
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Summary
Background: Chemo-radiotherapy is superior to radiotherapy
alone in the treatment of advanced, inoperable head and neck
cancer. The long-term treatment results, the induction of sec-
ond malignant tumors, and other long-term toxicities are not
well defined. Patients and Methods: 100 consecutive patients
with advanced head and neck cancer who were treated at our
center were studied. Treatment results, survival, the occurrence
of late complications, and second malignant tumors (SMT)
were investigated. 78 patients were treated with a protocol
combining cisplatinum, 5-fluorouracil, folinic acid and hyper-
fractionated irradiation. 22 patients were treated with other
chemo-radiotherapy protocols. The relative risk of developing
an SMT was compared with that within the normal population.
Results: The cumulative total probability of survival was 51.1%
at 2 years and 38.7% at 4 years. The probability of relapse-free
survival was 39.9% at 2 years and 36.7% at 4 years. A total of 7
patients developed SMT (4 cases of lung cancer, 2 colon can-
cers, 1 skin cancer). After 6 years, a cumulative risk of SMT of
8.7% was observed. The relative risk of developing an SMT was
significantly increased (4.45-fold in males) compared with a
normal population. 13 of 38 evaluable patients (34.2%) had se-
vere late complications like fibrosis of soft tissues, nerve le-
sions, or were dependent on tracheal cannulas. Conclusions:
The treatment results and long-term prognoses in our popula-
tion of unselected high-risk patients are unsatisfactory, but
comparable to those from multicenter studies. About 35% of
patients become long-term (> 4 years) survivors. SMT generally
occur early, have a poor prognosis and, most likely, are not
treatment-related. Approximately 30% of long-term survivors
have severe, often incapacitating late effects. The treatment and
– if possible – prevention of these late effects is important for
the quality of life of patients who survived advanced head and
neck cancer. 
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Introduction
In the 1980s, patients with locoregionally advanced head and
neck cancer had a poor prognosis. Conventional therapy,
surgery and radiation, led to long-term survival or even cure
in fewer than 20% of patients. The introduction of platinum-
based chemo-radiotherapy has improved the response and
possibly the cure rate of patients with advanced head and
neck cancer and can now be considered as the standard of
care [1–3]. The rationale of chemo-radiotherapy with hyper-
fractionated irradiation is that tumor cells are sensitized to ra-
diation and thereby the resistance of tumor cells is overcome.
A meta-analysis of 63 trials concluded that chemotherapy
added to locoregional treatment provided a benefit in survival
rate of 4% at 2 and at 5 years [4]. It is known that modern
chemo-radiotherapy entails a considerable acute toxicity (e.g.
mucositis) and some long-term complications like radiation fi-
brosis and xerostomia. In addition, the treatment of patients
with head and neck cancer is complicated by comorbidity. If
all types of cancer are considered, the induction of second ma-
lignant tumors (SMT) is a serious problem [5]. For example,
the long-term treatment results of patients with Hodgkin’s dis-
ease and testicular cancer are negatively influenced by the oc-
currence of SMT. Patients with head and neck cancer are pre-
disposed to second tumors by the field cancerization due to
tobacco and other carcinogens. Additional factors may be ge-
netic influences, age, and treatment-related factors. Previous
studies reported a widely different incidence of second cancer
after the diagnosis of head and neck cancer [6, 7]. Recently,
Merlano et al. [8] reported that patients with head and neck
cancer treated with chemo-radiotherapy developed more sec-
ond cancers than patients treated only with radiation. Howev-
er, in that study , the total survival was still superior in the
group of patients treated with chemo-radiotherapy compared
to the radiation group. In the present study we investigated
the patients treated at our center with combined chemo-ra-
diotherapy for the long-term treatment results, late complica-
tions and for the occurrence of SMT. 
Patients and Methods
All patients treated at our center between January 1988 and June 2000 (10
years and 6 months) with combined chemo-radiotherapy were included in
the present study. 4 patients were excluded because the records were in-
sufficient, and 3 patients were excluded because of a preexisting malig-
nant tumor. Clinical characteristics of the patients are shown in table 1. 78
patients were treated with an intensive protocol combining cisplatinum, 5-
fluorouracil, folinic acid and hyperfractionated irradiation [1, 2]. The re-
maining 22 patients were treated with less intensive chemo-radiotherapy,
mainly because of age and reduced performance status. In these 22 pa-
tients, combinations of 5-fluorouracil and mitomycin-C were used as
chemotherapy. 
Before beginning the treatment, 24 patients underwent a surgical tumor
reduction (13 patients had radical neck dissection, 2 patients had radical
neck dissection and radical tumor surgery, 5 patients had a palliative
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tumor reduction, and 4 patients had a palliative tumor reduction and a se-
lective neck dissection). In 3 patients, a tracheostomy was necessary be-
fore beginning the treatment. 
Fractionated radiotherapy was performed with a cobalt-60 source
(Siemens Gammatron-1; patients treated until 9/97) and a linear accelera-
tor (Siemens Linac MD-2; patients treated after 9/97). Treatment plan-
ning was individualized by computed tomography. Amifostine was not
routinely administered during radiotherapy.
Follow-up was obtained from outpatient records, and by contacting the
patient or his physician by telephone. Follow-up was complete in 96 cases
(information about clinical status within 12 months of last attempted con-
tact). A complete clinical response was defined as no evidence of disease
3 months after combined treatment. If radiological abnormalities persist-
ed, the patient was evaluated at the next follow-up visit, and was termed
complete response if no progression had developed. 
Late effects were evaluated if the patient had survived at least 1 year after
diagnosis, did not have an SMT, and was available for an interview or if
adequate records were present. 
The diagnosis of SMT was made if a tumor showed a histology different
from that of the initial tumor and/or a clinical presentation of a second un-
related tumor. 
Statistical Methods
Survival, relapse-/progression-free survival and the occurrence of SMT
were estimated by Kaplan-Meier analysis. SPSS, version 10, was used for
data analysis and statistical calculations. Patients who developed SMT
were censored for relapse-/progression-free survival. 
38 patients were evaluable for treatment-related late effects (median fol-
low-up 46 months after diagnosis). Dryness of mouth of any degree, hy-
pothyroidism, altered taste, hoarseness were considered as minor compli-
cations. Bone necrosis, chronic ulcers, fistulas, nerve lesions, laryngeal or
esophageal stenoses were considered as major complications. 
Age (years) at diagnosis    
Mean ± SD 54.55 ± 8.53   
Median 54.5  
Range  36–72     
Follow-up (months after diagnosis)
Mean ± SD 26.5 ± 30.5   
Median 13.9  
Range  1–127    
n  
Total number of patients  100  
Females   11  
Males   89     
UICC stage   
II     2  
III     9  
IV   89     
Site of disease   
Oropharynx   51  
Hypopharynx   24  
Larynx     7  
Oral cavity     9 
Other and combined sites     9  
SD = Standard deviation.   
Table 1. Patient 
characteristics
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As a reference data base for the tumor incidence in the general popula-
tion, the Saarland cancer registry was used (reference year 1996). For the
calculation of relative risk of SMT, the categories 141, 143–149, 161 (ICD
9) were excluded. Age- and gender-specific incidence rates from the nor-
mal population were multiplied by the corresponding person-years of ob-
servation to obtain the expected number of tumors. The estimation of rel-
ative risk (ratio of observed to expected number of cases) was based on
the assumption that the observed number of SMT followed a Poisson dis-
tribution. Confidence intervals for relative risks were calculated using
exact Poisson limits. The estimation of relative risk is statistically signifi-
cant if the confidence intervals do not overlap the unity. 
Results
Survival and Relapse-Free Survival
The total survival rates are shown in figure 1a. At 24 months,
the total cumulative survival probability was 51.1%, at 48
months it was 38.7%. If only patients are considered who had
an intensive cisplatinum-containing chemotherapy, the total
cumulative survival rate was 56.6% at 2 years and 44.3% at 4
years. The Kaplan-Meier analysis for these patients in com-
parison with other chemo-radiotherapy regimens is shown in
figure 1b. If patients are considered who are aged 54 or
younger and compared with older patients, the younger pa-
tients survived slightly longer than older patients (mean sur-
vival time 51 versus 46 months). However, the Kaplan-Meier
analysis showed no significant difference between younger
(<55 years) and older patients (fig. 1c). No significant differ-
ence could also be found for sex, extent of disease (stage III
versus stage IV), and location (oropharynx and oral cavity
versus larynx and hypopharynx, data not shown). The analysis
of relapse- or progression-free survival time is shown in figure
2. The cumulative survival probability at 24 months for re-
lapse- or progression-free patients was 39.9%, at 48 months it
was 36.7%. A total of 20 patients survived 4 or more years
without evidence of relapse. A complete clinical response was
found in 43/76 evaluable patients (56.6%). 
Second Malignant Tumors
A total of 7 patients developed SMT (4 lung cancers, 2 colon
cancers and one basal cell skin cancer; table 2). The cumula-
tive incidence of SMT is shown in figure 3. After 6 years, a cu-
Patient Age Sex Histology Interval   
No. years (first to second cancer)
1 65  m lung cancer (squamous) 8 months  
2 66  m colon cancer 5 months  
3 61  m lung cancer (adenocarcinoma) 2 years   
4 45  m basal cell skin cancer 8 years  
5 71  m colon cancer 6 years   
6 52  m lung cancer (squamous) 0 months (synchronous)  
7 48 m lung cancer (squamous) 13 months  
Table 2. Second malignant tumors observed
after the treatment of advanced head and neck
cancer
Category  Number of cases Relative risk Absolute risk per 
observed/ expected (95% conf. interv.) 10,000 person-years 
All patients 7/1.71 4.09 (2.82–7.79) 268.5  
Male patients 7/1.57 4.45 (2.11–8.47) 305.0  
Female patients 0/0.14 0 (n.a.) n.a.
n.a. = Not applicable.  
Table 3. Relative and absolute risk of second
malignancy following head and neck cancer
n % 
Total number of patients evaluable  38  
1) No complications 0/38  
2) Minor complications 25/38 65.8 
3) Major complications 13/38 34.2 
Osteonecrosis 3  
Dependency on tracheal cannula 3  
Severe nerve lesions 2  
Other problems (persisting ulcers, severe problems of deglutition, others) 5
Table 4. Late complications observed after the
treatment of advanced head and neck cancer
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Late Complications
All patients had some degree of functional impairment fol-
lowing chemo-radiotherapy. In 13/38 patients (34.2%) major
late complications were observed (table 4). If only patients in
complete remission and with more than 4 years of follow-up
were considered, major complications were seen in 9/19 evalu-
able patients (47.4%). 
Discussion
Our treatment results of chemo-radiotherapy in patients with
advanced head and neck cancer are comparable to those from
large multicenter and single-center studies [1, 2, 8, 10–12]. Ap-
proximately 50% of patients survived for 2 years, and approx-
imately 35% survived free from relapse or progression for 4
years. These results were reached despite a majority of stage
IV patients and a median age of 54 years. The treatment re-
sults published here appear similar to those of a phase II study
published a decade earlier [13]; however, in the earlier study
only selected patients with a mean age of 47 years were treat-
ed. The present results actually show an improvement in the
standard of care, most likely due to advances in supportive
care. Of all patients who fail treatment, most die from tumor
progression, some die from treatment complications or SMT.
The development of second, histogenetically unrelated neo-
plasms is a problem recognized in patients with Hodgkin’s dis-
ease [5, 10] and other good-prognosis tumors like testicular
cancer [14], but may also be observed in other tumors. It was
Fig. 1. Total survival rates of patients with advanced head and neck can-
cer (Kaplan-Meier plots).  = Surviving patients; + = measurement.
a Patients treated with chemo-radiotherapy. b Patients treated with
chemo-radiotherapy (curve A: patients treated with cisplatinum-based
regimen; curve B: patients with other chemotherapy regimens). c Patients
treated with chemo-radiotherapy according to age (curve A: patients aged
54 years or younger; curve B: older patients).
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mulative risk of 8.7%, after 8 years a cumulative risk of 16.3%
was observed. All patients with SMT were male. The interval
between the diagnosis of head and neck cancer and SMT var-
ied between 0 months and 8 years (median time to diagnosis
of SMT: 13 months). In 5 patients the primary head and neck
tumor was in remission, in 2 patients active tumor was pre-
sent. The prognosis of patients with SMT was generally poor:
the 4 patients with lung cancer survived 1, 2+, 4+ and 13
months after the diagnosis of SMT, both patients with colon
cancer survived only 3 months after the diagnosis of SMT. The
relative risk of developing an SMT was significantly increased
(4.45-fold in males, 4.09-fold if both sexes are considered)
compared with a normal population (table 3).
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shown earlier that some SMT are related to the treatment ad-
ministered. In patients with head and neck cancer, the contin-
ued influence of carcinogens like tobacco and alcohol may
lead to second cancer. Previous studies indicate that 10–30%
of patients develop SMT [6, 7, 15–18]. However, these studies
include patients treated in the 1980s, in different stages and
with different treatment modalities. Few studies examine pa-
tients treated with combined chemotherapy and radiation for
their risk of SMT. A list of studies involving chemo-radiother-
apy is given in table 5. Our study shows that the risk of SMT is
present, and is statistically different from that of the normal
population. The type of tumors and the time frame in which
these tumors occur indicate that SMT are most likely related
to the carcinogens implicated in the primary cancer and are
not treatment-related. Typical treatment-related SMT are
leukemias following intensive treatment with alkylating agents
or sarcomas in the field of radiation. Some cases of apparent
SMT may actually represent metastasis of the primary cancer.
This was shown by microsatellite analysis in 10/16 cases of
lung cancer following head and neck cancer [26]. In our series,
patients No. 1, 6 and 7 might fall into this category. Even in
2/16 cases of esophageal cancer following head and neck can-
cer, a clonal relationship to the primary head and neck cancer
could be demonstrated [27]. However, the longer survival and
possible cure of a fraction of patients treated with chemo-ra-
diotherapy will favor the appearance of SMT. At present, the
major problem in advanced head and neck cancer is local re-
lapse and refractory disease, not death from SMT. A prospec-
tive comparison with patients who were treated with unique
radiation may determine to what extent SMT are influenced
by chemotherapy. Laser surgery should also be integrated in
the concept of multimodal treatment and may lead to a fur-
ther improvement in the long-term prognosis [28].
Quality of life issues are increasingly important for patients
with head and neck cancer [29, 30]. Most studies focus on
acute toxicities, swallowing disabilities, dry mouth, hoarseness,
and mouth pain. These studies generally examine the acute
treatment period and at most 12 months beyond. Recently, a
randomized study in patients with head and neck cancer
showed that a radioprotector (amifostine) ameliorates some
of the late toxicities (xerostomia) of chemo-radiotherapy [31].
Our study investigated late toxicities like nerve lesions,
esophageal stenosis, and osteonecrosis. All patients had some
degree of functional impairment. A surprisingly high number
of patients (30–40%) had major late effects. The current ag-
gressive approach has increased the cure rate in advanced
head and neck cancer. With longer follow-up, more patients
may develop late toxicities. A prospective comparison may
determine to what extent late sequelae are due to chemother-
apy and radiation. For the optimal quality of life, it is impor-
tant to recognize, treat and, if possible, prevent these late tox-
icities.
Fig. 2. Relapse- and progression-free survival of patients with advanced
head and neck cancer treated with chemo-radiotherapy.
Fig. 3. Cumulative incidence of SMT in patients with advanced head and
neck cancer treated with chemo-radiotherapy.
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Table 5. Risk of second malignant tumors after the treatment of advan-
ced head and neck cancer with chemo-radiotherapy (literature data)
Study  Cumulative risk Number of cases  
Present study  16.3% after 8 years 7/100  
SECOG, 1986 [19] –a –a
Franchin et al., 1995 [20] –a 5/46  
Merlano et al., 1996 [8] 7.6% (no date) 10/80  
Dinges et al., 1997 [21] –a –a
Haffty et al., 1997 [11] –a 12/91  
Abitbol et al., 1997 [22] –a 3/70  
Brizel et al., 1998 [23] –a –a
Schrader et al., 1998 [12] –a (no details)  
Vokes et al., 2000 [24] ≈ 15% at 4 years 4/76   
Jeremic et al., 2000 [25] –a –a
a Not mentioned.
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